Overtreatment is considered harmful in terms of decreasing quality of life, wasting resources, and environmental damage.1–3 These risks are especially relevant when considering adjuvant chemotherapy ...

In a Phase II trial, advanced ovarian patients with HRD alterations seemed to fare particularly well on Imunon's IMNN-001 plus standard chemo.

Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening ...

Illumina Inc. (NASDAQ: ILMN) today announced the launch of the next generation of TruSight Oncology 500, its flagship cancer research assay that enables comprehensive genomic profiling. Comprehensive ...

It is the story of Chernobyl’s feral dogs, and it begins not with a whimper but with a nuclear boom a boom that, some four decades ago, transformed a thriving village into a zone of exclusion, and ...

Since 2022, India has a scientifically proven, indigenous Lumpy Skin Disease-specific vaccine readily available but there has ...

意大利罗马Agostino Gemelli综合医院妇科肿瘤科Vanda ...

Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening ...

Discover the latest breakthroughs in oncology, including pivotal FDA decisions, promising therapies, and new treatment options for multiple myeloma and ovarian cancer.

PDF for Biology from the official Rajasthan Board website. Access chapter-wise details for Biology with the link to download ...

Senhwa Biosciences begins patient dosing in NCI-sponsored pilot study of Pidnarulex pharmacodynamics in patients with advanced solid tumours: Taipei, Taiwan Thursday, July 17, 202 ...

The company, which spun out of a Korean institute, said its test has been listed at 10 leading hospitals and academic centers.